Felix, Gabriela E. S.
Guindalini, Rodrigo Santa Cruz
Zheng, Yonglan
Walsh, Tom
Sveen, Elisabeth
Lopes, Taisa Manuela Machado
Côrtes, Juliana
Zhang, Jing
Carôzo, Polyanna
Santos, Irlânia
Bonfim, Thaís Ferreira
Garicochea, Bernardo
Toralles, Maria Betânia Pereira
Meyer, Roberto
Netto, Eduardo Martins
Abe-Sandes, Kiyoko
King, Mary-Claire
de Oliveira Nascimento, Ivana Lucia
Olopade, Olufunmilayo I. http://orcid.org/0000-0002-9936-1599
Funding for this research was provided by:
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (Código de Financiamento – 001)
American Cancer Society
John and Editha Kapoor Charitable Foundation
Susan G. Komen for the Cure (SAC110026)
National Cancer Institute Specialized Programs of Research Excellence (P20CA233307)
Secretaria de Saúde do Estado da Bahia
Fundação de Apoio à Pesquisa e Extensão – FAPEX
Paul Calabresi Career Development Award for Clinical Oncology (K12 CA139160)
Article History
Received: 9 November 2021
Accepted: 27 February 2022
First Online: 30 March 2022
Declarations
:
: OIO is a cofounder at CancerIQ and has equity in Tempus and 54gene. RSCG acted as a consultant for AstraZeneca, GlaxoSmithKline, and Igenomix; received speaker honoraria from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Merck Sharp & Dohme, Novartis and Roche outside the submitted work; and has equity in Mendelics Análise Genômica. TW consults for Color Genomics. The other authors made no disclosures.
: This research was approved by research ethics committees or institutional review boards of all participating institutions in Brazil and the United States.
: All studied subjects gave informed written consent upon enrollment in the study.
: All studied subjects and researchers involved in this study consent to publishing the data.